PharmX Technologies Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Tom Culver

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	2.8yrs
Promedio de permanencia en la Junta Directiva	3.8yrs

Actualizaciones recientes de la dirección

Recent updates

At AU$0.089, Is It Time To Put Corum Group Limited (ASX:COO) On Your Watch List?

Apr 29

Corum Group (ASX:COO) Is Posting Healthy Earnings, But It Is Not All Good News

Mar 02

Corum Group Limited (ASX:COO) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?

Dec 13

CEO

Tom Culver

less than a year

Permanencia

Mr. Tom Culver serves as Head of Wealth & Crypto Services at Douugh Limited since January 2021. Mr. Culver is Goodments Founder & CEO. Mr. Culver is Chief Executive Officer of PharmX Technologies Limited f...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Zoe Hillier	Chief Financial Officer	2.8yrs	AU$257.32k	0.063% A$ 11.3k
James Nevile	Chief Operating Officer	2.8yrs	AU$310.49k	0.042% A$ 7.5k
Tom Culver	Chief Executive Officer	less than a year	sin datos	sin datos
Eryl Baron	Company Secretary	3.4yrs	sin datos	sin datos

2.8yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de PHX se considera experimentado (2.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Dennis Bastas	Non-Executive Director	3.3yrs	AU$83.00k	10.02% A$ 1.8m
Jayne Shaw	Independent Non-Executive Director	3.5yrs	AU$97.24k	0.46% A$ 83.4k
Andrew Jonathan Newbery	Non-Executive Director	4.2yrs	AU$97.24k	0.29% A$ 51.4k
Nick England	Non-Executive Chairman	4.4yrs	AU$504.83k	4.51% A$ 809.4k

3.8yrs

Permanencia media

Junta con experiencia: La junta directiva de PHX se considera experimentada (3.8 años de antigüedad promedio).

PharmX Technologies Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

PharmX Technologies Limited Announces the Appointment of Tom Culver as Chief Executive Officer, Effective 20 November 2023

PharmX Technologies Limited Announces the Appointment of Tom Culver as Chief Executive Officer, Effective 20 November 2023

PharmX Technologies Limited, Annual General Meeting, Nov 21, 2023

No independent directors

Corum Group Limited, Annual General Meeting, Nov 14, 2022

No independent directors

Recent updates

First half 2024 earnings released: EPS: AU$0 (vs AU$0.001 loss in 1H 2023)

PharmX Technologies Limited to Report First Half, 2024 Results on Feb 23, 2024

Now 27% overvalued

What Is PharmX Technologies Limited's (ASX:PHX) Share Price Doing?

New major risk - Market cap size

New minor risk - Share price stability

PharmX Technologies Limited Announces the Appointment of Tom Culver as Chief Executive Officer, Effective 20 November 2023

PharmX Technologies Limited Announces the Appointment of Tom Culver as Chief Executive Officer, Effective 20 November 2023

PharmX Technologies Limited, Annual General Meeting, Nov 21, 2023

New major risk - Revenue and earnings growth

Full year 2023 earnings released: AU$0.002 loss per share (vs AU$0 in FY 2022)

Corum Group Limited to Report Fiscal Year 2023 Results on Aug 23, 2023

Jonas Software AUS Pty Ltd entered into an agreement to acquire Corum Health Pty Ltd and Amfac Pty Ltd. from Corum Group Limited (ASX:COO) for AUD 6.3 million.

A Look At The Intrinsic Value Of Corum Group Limited (ASX:COO)

At AU$0.044, Is Corum Group Limited (ASX:COO) Worth Looking At Closely?

First half 2023 earnings released: AU$0.001 loss per share (vs AU$0 in 1H 2022)

No independent directors

Corum Group Limited, Annual General Meeting, Nov 14, 2022

Full year 2022 earnings released: EPS: AU$0 (vs AU$0.002 in FY 2021)

Corum Group Limited Launches Pharmxchange Platform

No independent directors

Zenith Payments Pty Ltd completed the acquisition Real Estate eCommerce business unit of Corum Group Limited from Corum Group Limited (ASX:COO).

First half 2022 earnings: EPS and revenues miss analyst expectations

Corum Group Limited to Report First Half, 2022 Results on Feb 10, 2022

Corum Group Limited Announces Resignation of Julian Sallabank as Managing Director

Zenith Payments Pty Ltd agreed to acquire Real Estate eCommerce business unit of Corum Group Limited from Corum Group Limited (ASX:COO) for AUD 0.5 million.

Is Now The Time To Put Corum Group (ASX:COO) On Your Watchlist?

Full year 2021 earnings released: EPS AU$0.002 (vs AU$0.001 in FY 2020)

At AU$0.089, Is It Time To Put Corum Group Limited (ASX:COO) On Your Watch List?

Corum Group (ASX:COO) Is Posting Healthy Earnings, But It Is Not All Good News

First half 2021 earnings released: EPS AU$0.002 (vs AU$0.001 loss in 1H 2020)

Corum Group Limited to Report First Half, 2021 Results on Feb 24, 2021

Corum Group Limited (ASX:COO) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?

Corum Group Limited Announces Appointment of Dennis Bastas to the Board of Directors

Corum Group Limited Appoints Eryl Baron as Company Secretary, Effective 3 November 2020

Corum Group Limited Appoints Jayne Shaw to its Board of Directors

Corum Group Limited (ASX:COO) completed the acquisition of remaining 57% stake in PharmX Pty Ltd from Mountaintop Systems Pty. Ltd. and Daleflag Pty Ltd.

Corum Group Limited (ASX:COO) entered into a binding agreement to acquire remaining 57% stake in PharmX Pty Ltd from Mountaintop Systems Pty Ltd and Daleflag Pty Ltd for AUD 7.9 million

Corum Group Limited (ASX:COO) completed the acquisition of an unknown additional minority stake in PharmX Pty Limited from Fred IT Group Pty Ltd.

CEO

Permanencia

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media